TABLE 1.
Comparison of undetected or underquantified viral load as determined by the Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and Biomerieux NucliSens QT assays
| Assay | Subtypea (p24/pol) | No. of samples | Log deviationc (range) | No. of deviant samples/samples tested |
|---|---|---|---|---|
| Roche Amplicor Monitor v1.5 | F/F | 1 | 4.68 | 2/430 |
| FB/BF | 1 | 4.23 | ||
| Bayer Versant bDNA v3.0 | B/B | 1 | 5.58 | 3/442 |
| C/C | 1 | 2.40 | ||
| F/C | 1 | 4.49 | ||
| Biomerieux NucliSens HIV-1 QT | B/B | 11 | 4.54 (2.3-5.7) | 14/323 |
| F/recb | 3 | 3.99 (1.7-5.5) |
Phylogenetic analysis comprised HXB2 genome residues 1345 to 1839 and HXB2 2266 to 3257. The primer sequences used for amplification and sequencing were HXB2 886 to 908, 1307 to 1328, 1344 to 1363, 1344 to 1369, 2155 to 2174, 2220 to 2242, 2600 to 2620 (sense) and 2176 to 2152, 1843 to 1822, 1736 to 1760, 1654 to1675, 3334 to 3311, 3308 to 3288, and 3298 to 3276 (antisense). Typing of the circulating recombinant form was based on SimPlot analysis of gag (p24)/pol genes.
Includes one F/B, one F/BF, and one F/FB gag (p24)/pol recombinant sample.
The median expressed as log10(LTR assay − commercial assay).